Stereotactic Radiation Plus New Hormone Therapy for Prostate Cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a targeted, high-dose radiation therapy (SBRT) plus a newer hormone drug (abiraterone or enzalutamide) for men whose prostate cancer has spread to a small number of spots (5 or fewer) and is no longer controlled by standard hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Prostate cancer confirmed by biopsy
- Testosterone at castration levels (below 50 ng/mL)
- Disease progression despite low testosterone (by blood test or scan)
- 5 or fewer metastases in lymph nodes or bones (no spread to organs)
- Planning to start or recently started abiraterone or enzalutamide (within 14 days)
- No prior docetaxel for castration-resistant prostate cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
This study is testing whether using focused radiation beams (SBRT) right away or later, along with hormone therapy, can help control prostate cancer that has returned in a few spots outside the pelvis. The goal is to find the best timing for combining radiation and hormone treatment.
This trial tests a shorter course of hormone therapy plus targeted radiation for prostate cancer that has spread to a few spots (oligometastatic). The goal is to see if less hormone therapy can still control the cancer effectively.
This study tests adding a targeted local treatment (like radiation or surgery) to standard hormone therapy for men with advanced prostate cancer that still shows up on a special scan. The goal is to see if this combination helps control the cancer better.
Hear when a new Prostatic Neoplasms, Castration-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.